Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Sales of the problematic Amgen Inc. drug Tavneos resumed late last week in Japan with a new warning label after several ...

Amgen (AMGN) offers market-beating returns, a strong drug pipeline, and value at 15.1x forward P/E plus a 3% yield.

Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

He will return to Amgen on July 1 as Executive Vice President, transitioning into the Chief Financial Officer role on Sep ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ‌citing ⁠a lack of proven ...